Literature DB >> 1962086

Mycobacterium kansasii infections in patients positive for human immunodeficiency virus.

J L Carpenter1, J M Parks.   

Abstract

The experience with Mycobacterium kansasii infections in patients who are infected with human immunodeficiency virus (HIV) at Parkland Memorial Hospital in Dallas is presented, and the literature on such infections is reviewed. The absolute and relative paucity of reports of M. kansasii infections in HIV-positive patients is emphasized. M. kansasii infections in HIV-positive patients are classified as either pulmonary or disseminated. Evidence of the lack of therapeutic response in patients with disseminated infections and of the potential for therapeutic response in patients with infections limited to the lung is reviewed and documented. Other unresolved diagnostic and therapeutic issues concerning M. kansasii infections in HIV-positive patients are reviewed.

Entities:  

Mesh:

Year:  1991        PMID: 1962086     DOI: 10.1093/clinids/13.5.789

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  9 in total

1.  In vitro susceptibility of Mycobacterium kansasii to clarithromycin.

Authors:  J Biehle; S J Cavalieri
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Large-restriction-fragment analysis of Mycobacterium kansasii genomic DNA and its application in molecular typing.

Authors:  Y Iinuma; S Ichiyama; Y Hasegawa; K Shimokata; S Kawahara; T Matsushima
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

3.  Nasal Mycobacterium kansasii infection in a patient with acquired immunodeficiency syndrome.

Authors:  E Tortoli; M T Simonetti; D Dionisio
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-07       Impact factor: 3.267

4.  Mycobacterium kansasii: its presentation, treatment and outcome in HIV infected patients.

Authors:  G Rooney; M R Nelson; B Gazzard
Journal:  J Clin Pathol       Date:  1996-10       Impact factor: 3.411

5.  CT findings of pulmonary non-tuberculous mycobacterial infection in non-AIDS immunocompromised patients: a case-controlled comparison with immunocompetent patients.

Authors:  Y Lee; J-W Song; E J Chae; H J Lee; C-W Lee; K-H Do; J B Seo; M-Y Kim; J S Lee; K-S Song; T S Shim
Journal:  Br J Radiol       Date:  2013-02-25       Impact factor: 3.039

6.  Molecular analysis of Mycobacterium kansasii isolates from the United States.

Authors:  Yansheng Zhang; Linda B Mann; Rebecca W Wilson; Barbara A Brown-Elliott; Véronique Vincent; Yoshitsugu Iinuma; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

7.  Potential role of roxithromycin against the Mycobacterium avium complex.

Authors:  L S Young; L E Bermudez; M Wu; C B Inderlied
Journal:  Infection       Date:  1995       Impact factor: 3.553

8.  Complete Genome Sequences of Mycobacterium kansasii Strains Isolated from Rhesus Macaques.

Authors:  Aruna Panda; Sushma Nagaraj; Xuechu Zhao; Hervé Tettelin; Louis J DeTolla
Journal:  Genome Announc       Date:  2017-04-20

9.  Clinical and Microbiological Characteristics of Mycobacterium kansasii Pulmonary Infections in China.

Authors:  Yinjuan Guo; Yanhua Cao; Haican Liu; Jinghui Yang; Weiping Wang; Bingjie Wang; Meilan Li; Fangyou Yu
Journal:  Microbiol Spectr       Date:  2022-01-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.